A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

NCT01761266 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

954

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Lenvatinib
DRUG: Sorafenib

Sponsor

Eisai Limited

Collaborators

[object Object]